All News

covid vaccine

FDA Approves First COVID-19 Vaccine

Jack Cush, MD

Today, the U.S.

Read Article
RheumNow Podcast square

RheumNow Podcast – Driving in Pain (8.20.2021)

Jack Cush, MD

You know, I'm a very good driver. We all think we're great drivers - but consider what it's like to drive in pain: would you be a good driver? Also, I want you to consider the diagnosis of calcium pyrophosphate dihydrate disease (CPPD). But first, let's look at a study out of Scotland, looking at military service and greater risk of hip and knee replacement.

Read Article
vaccine,mRNA,Covid,vial

Sustained Effectiveness of mRNA Vaccines Against COVID-19 Hospitalizations

MMWR

The CDC has reported that mRNA vaccine effectiveness against COVID-19–associated hospitalizations was sustained over 24 weeks; but there is evidence of waning protection amongst the immunosuppressed.

Read Article
COVID,vaccinate,injection,green

HHS, FDA & CDC Joint Recommendation on COVID Booster

FDA

Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people.

Read Article
vaccination.jpg

Booster Shots for Rheumatology Patients on Immunosuppressive Medications

ACR Press Release

ATLANTA – The CDC's Advisory Committee on Immunization Practices today recommended that rheumatology patients being actively treated with high-dose corticosteroids, alkylating agents, antimetabolites, TNF blockers, and other biologic agents that are immunosuppressive or immunomodulatory receive a third dose of the Pfizer-BioNTech or Moderna mRNA COVID-19 vaccines.

Read Article
RheumNow Podcast square

RheumNow Podcast – Booster Shots for COVID (8.13.2021)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article
injection-green.jpg

Anakinra's Effects on COVID-19 Outcomes

Jack Cush, MD

Sporadic reports of anakinra use in COVID-19 infection has hinted is potential; now a metanalysis shows that the use of anakinra may reduce the mortality risk in patients admitted to hospital with moderate to severe COVID-19 pneumonia, especially highly elevated ferritin and C-reactive prote

Read Article
Most recent numbers from the CDC - The agency said 202,041,893 people had received at least one dose while 171,367,657 people are fully vaccinated as of Tuesday. https://t.co/3rp7QMt84y

Links:

Dr. John Cush RheumNow ( View Tweet)

Breakthrough infections: As of Aug. 9, almost 74% of the 8,054 vaccinated people that were hospitalized with COVID-19 were above the age of 65, according to the U.S. Centers for Disease Control and Prevention. ~20% of those cases ended in deaths https://t.co/jaSmKv5pPS

Links:

Dr. John Cush RheumNow ( View Tweet)

The CDC has reported that mRNA vaccine effectiveness against COVID-19–associated hospitalizations was sustained over 24 weeks; but there is evidence of waning protection amongst the immunosuppressed. https://t.co/UpQjFgKTpE https://t.co/3dQ2jacwJD

Links:

Dr. John Cush RheumNow ( View Tweet)
Are you holding Otezla, SSZ, or leflunomide post vaccination? @RheumNow @LCalabreseDO @CCalabreseDO @DrDavidKarp @RADoctor @JointMD @JYazdanyMD

k dao KDAO2011 ( View Tweet)

@AngusWorthing @rheumecraig @ravenswoodrheum @JointMD @RheumNow @LCalabreseDO @CCalabreseDO @DrDavidKarp @RADoctor @JYazdanyMD @alhkim Do we have data that NSAIDS and acetaminophen alter antibody response? I would rather pts take acetaminophen or ibuprofen post-vax than prednisone.

k dao KDAO2011 ( View Tweet)

In case you missed it— Booster Shots for Rheumatology Patients on Immunosuppressive Medications https://t.co/dIzrv3B12u https://t.co/2x63osTNHh

Links:

Dr. John Cush RheumNow ( View Tweet)
HHS, FDA & CDC Joint Recommendation on COVID Booster https://t.co/pKlFjnlQeu https://t.co/ue0pMfEvfm

Links:

Dr. John Cush RheumNow ( View Tweet)
Sporadic reports of anakinra use in COVID-19 infection has hinted is potential; now a metanalysis shows that the use of anakinra may reduce the mortality risk in patients admitted to hospital with moderate to severe COVID-19 pneumonia. https://t.co/VBxg9fQmt0 https://t.co/ARX2C0WRJ1

Links:

Dr. John Cush RheumNow ( View Tweet)
16 Pts on mech ventilation for SARS-CoV-2- induced ARDS with hyperinflammation were treated with ruxolitinib plus standard care - 13/16 survived 28 days. Better outcomes seen w/ RUX and Lymph-neutrophil ration > 0.07. https://t.co/4O2Y5swE0x

Links:

Dr. John Cush RheumNow ( View Tweet)

In the week ending 8/12: 👧🏽121,427 pediatric #COVID19 cases (14.4% of all cases, 49 states) 🏥452 pediatric hospitalizations (24 states reporting) 💀7 pediatric deaths (43 states reporting) One death is too many.

Shematologist, MD acweyand ( View Tweet)

https://t.co/VBxg9fQmt0 Sporadic reports of anakinra use in COVID-19 infection has hinted is potential; now a metanalysis shows that the use of anakinra may reduce the mortality risk in patients admitted to hospital with moderate to severe COVID-19 pneumonia... https://t.co/XIB7OVNCvT

Links:

Dr. John Cush RheumNow ( View Tweet)
New study data on mRNA vaccines in pts with inflammatory diseases on mostly #TNFi +/- #csDMARDs . ▶️ Effective immune response (lower than healthy controls) ▶️Comparable side effects ▶️ no ⬆️ in DAS28 ▶️ no pts on #Rituximab included https://t.co/aexdFoUzer https://t.co/h1S1S2YsHS

Links:

ARD & RMD Open ARD_BMJ ( View Tweet)
COVID Vaccine Booster Effective for Transplant Recipients in Small Trial For organ transplant recipients, a third dose of Moderna's COVID-19 vaccine more than tripled the proportion with a sufficient antibody response, a randomized trial showed. https://t.co/iD2WFfUP3a https://t.co/eYMdocd9T4

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×